Symbols / VINC $0.01 +0.00% Vincerx Pharma, Inc.
VINC Chart
Stock Fundamentals
|
|
|
|
|
|
About
Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company that develops differentiated and novel therapies to address the unmet medical needs of patients with cancer in the United States. Its VersAptx bioconjugation platform combines different targeting, linker, and payload technologies to develop antibody-drug conjugates (ADC) and small molecule drug conjugates (SMDC); and provides CellTrapper technology for use in reduction of payload cellular permeability. The company develops VIP943, an antibody drug conjugate in Phase 1 dose-escalation study for relapsed/refractory acute myeloid leukemia, higher-risk MDS, and B-cell acute lymphoblastic leukemia; VIP236, an SMDC, which is in Phase 1 dose-escalation study for the treatment of patients with advanced or metastatic solid tumors; and VIP924, an anti-CXCR5 ADC that leverages the same effector chemistry in preclinical studies for b-cell malignancies. It has a collaboration with the National Institutes of Health for the Phase 1 dose-escalation of enitociclib, a highly selective cyclin-dependent kinase 9 inhibitor. The company was formerly known as Vincera Pharma, Inc. and changed its name to Vincerx Pharma, Inc. in January 2021. Vincerx Pharma, Inc. was founded in 2019 and is headquartered in San Mateo, California.
Ratings
Current target
$0.01
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2024-10-08 | main | Leerink Partners | Outperform → Outperform | $2 |
| 2024-04-09 | reit | Cantor Fitzgerald | — → Overweight | — |
| 2024-04-01 | reit | Cantor Fitzgerald | — → Overweight | — |
| 2023-09-07 | reit | Cantor Fitzgerald | Overweight → Overweight | $5 |
| 2022-11-17 | main | Chardan Capital | — → Buy | $3 |
| 2022-08-12 | main | SVB Leerink | — → Outperform | $5 |
| 2022-06-08 | main | Cantor Fitzgerald | — → Overweight | $8 |
| 2022-06-07 | main | B. Riley Securities | — → Buy | $6 |
| 2022-06-07 | main | Chardan Capital | — → Buy | $4 |
| 2022-06-07 | main | SVB Leerink | — → Outperform | $6 |
| 2022-05-13 | main | Chardan Capital | — → Buy | $11 |
| 2022-05-13 | main | SVB Leerink | — → Outperform | $19 |
| 2022-03-30 | main | SVB Leerink | — → Outperform | $20 |
| 2022-03-30 | main | HC Wainwright & Co. | — → Buy | $28 |
| 2022-01-14 | init | HC Wainwright & Co. | — → Buy | $25 |
| 2021-12-23 | init | Cantor Fitzgerald | — → Overweight | $25 |
| 2021-11-01 | init | SVB Leerink | — → Outperform | $24 |
| 2021-09-13 | init | Laidlaw & Co. | — → Buy | $30 |
| 2021-08-25 | init | B. Riley Securities | — → Buy | $26 |
| 2021-08-13 | main | Chardan Capital | — → Buy | $30 |
- Vincerx Pharma Announces Complete Liquidation and Nasdaq Exit: What Happens to Your Shares? - Stock Titan hu, 17 Apr 2025 07
- Vinci Airports Q1 passenger traffic grows as Middle East conflict impact limited - Investing.com hu, 16 Apr 2026 07
- VINC Stock Price and Chart — OTC:VINC - TradingView hu, 24 Apr 2025 18
- Vincerx Pharma, Inc. Announces Intent to Delist from Nasdaq and Deregister with the SEC - Yahoo Finance hu, 17 Apr 2025 07
- Vincerx Pharma (VINC) Stock Price, News & Analysis $VINC - MarketBeat Wed, 06 Jan 2021 10
- VINC Stock Price, News & Analysis - Stock Titan Fri, 25 Apr 2025 00
- VINC Stock Price, Quote & Chart | VINCERX PHARMA INC (NASDAQ:VINC) - ChartMill Sat, 01 Jan 2022 01
- symbol__ Stock Quote Price and Forecast - CNN Sun, 03 Mar 2024 11
- Vincerx Pharma Inc. (VINC) reports earnings - qz.com hu, 27 Mar 2025 07
- Why Is Laser Photonics (LASE) Stock Up 130% Today? - InvestorPlace ue, 09 Apr 2024 07
- Financially struggling drugmaker's potential rescue falls apart. It now will wind down - San Francisco Business Times - The Business Journals ue, 08 Apr 2025 07
- Vince McMahon sells over $400 million worth of stock amid allegations - thestreet.com ue, 05 Mar 2024 08
- Vincerx Pharma Enters into a Binding Term Sheet for a Strategic Merger with Oqory, Inc. - Yahoo Finance Fri, 27 Dec 2024 08
- vincerx pharma cancels merger, initiates wind-down activities - Investing.com Fri, 11 Apr 2025 07
- Latest VINC News - Vincerx Pharma, Inc. Announces Additional A... - Stock Titan Wed, 23 Dec 2020 16
Insider Transactions
No recent insider transactions.
Financials
Statement View
| Line Item | Trend | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
31.46
-26.16%
|
42.61
-38.00%
|
68.72
+9.68%
|
62.66
|
| Research And Development |
|
15.49
-46.55%
|
28.97
-41.86%
|
49.84
+24.34%
|
40.08
|
| Selling General And Administration |
|
15.98
+17.17%
|
13.64
-27.79%
|
18.89
-16.35%
|
22.57
|
| General And Administrative Expense |
|
15.98
+17.17%
|
13.64
-27.79%
|
18.89
-16.35%
|
22.57
|
| Other Gand A |
|
15.98
+17.17%
|
13.64
-27.79%
|
18.89
-16.35%
|
22.57
|
| Total Expenses |
|
31.46
-26.16%
|
42.61
-38.00%
|
68.72
+9.68%
|
62.66
|
| Operating Income |
|
-31.46
+26.16%
|
-42.61
+38.00%
|
-68.72
-9.68%
|
-62.66
|
| Total Operating Income As Reported |
|
-31.46
+26.16%
|
-42.61
+40.15%
|
-71.19
-13.62%
|
-62.66
|
| EBITDA |
|
-30.37
+27.15%
|
-41.69
+38.49%
|
-67.78
-8.77%
|
-62.32
|
| Normalized EBITDA |
|
-30.56
+26.63%
|
-41.65
+41.85%
|
-71.62
+16.41%
|
-85.67
|
| Reconciled Depreciation |
|
1.09
+19.13%
|
0.92
-2.56%
|
0.94
+176.18%
|
0.34
|
| EBIT |
|
-31.46
+26.16%
|
-42.61
+38.00%
|
-68.72
-9.68%
|
-62.66
|
| Total Unusual Items |
|
0.18
+489.36%
|
-0.05
-101.23%
|
3.83
-83.59%
|
23.36
|
| Total Unusual Items Excluding Goodwill |
|
0.18
+489.36%
|
-0.05
-101.23%
|
3.83
-83.59%
|
23.36
|
| Special Income Charges |
|
—
|
0.00
+100.00%
|
-2.47
|
0.00
|
| Restructuring And Mergern Acquisition |
|
—
|
0.00
-100.00%
|
2.47
|
0.00
|
| Net Income |
|
-30.07
+25.11%
|
-40.16
+36.24%
|
-62.98
-60.24%
|
-39.31
|
| Pretax Income |
|
-30.07
+25.11%
|
-40.16
+36.24%
|
-62.98
-60.24%
|
-39.31
|
| Net Non Operating Interest Income Expense |
|
0.47
-62.27%
|
1.25
+88.40%
|
0.66
|
0.00
|
| Net Interest Income |
|
0.47
-62.27%
|
1.25
+88.40%
|
0.66
|
0.00
|
| Interest Income Non Operating |
|
0.47
-62.27%
|
1.25
+88.40%
|
0.66
|
0.00
|
| Interest Income |
|
0.47
-62.27%
|
1.25
+88.40%
|
0.66
|
0.00
|
| Other Income Expense |
|
0.92
-23.65%
|
1.20
-76.33%
|
5.07
-78.27%
|
23.35
|
| Other Non Operating Income Expenses |
|
0.73
-41.19%
|
1.25
+0.65%
|
1.24
+15600.00%
|
-0.01
|
| Gain On Sale Of Security |
|
0.18
+489.36%
|
-0.05
-100.75%
|
6.30
-73.02%
|
23.36
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-30.07
+25.11%
|
-40.16
+36.24%
|
-62.98
-60.24%
|
-39.31
|
| Net Income From Continuing Operation Net Minority Interest |
|
-30.07
+25.11%
|
-40.16
+36.24%
|
-62.98
-60.24%
|
-39.31
|
| Net Income From Continuing And Discontinued Operation |
|
-30.07
+25.11%
|
-40.16
+36.24%
|
-62.98
-60.24%
|
-39.31
|
| Net Income Continuous Operations |
|
-30.07
+25.11%
|
-40.16
+36.24%
|
-62.98
-60.24%
|
-39.31
|
| Normalized Income |
|
-30.26
+24.56%
|
-40.11
+39.97%
|
-66.82
-6.63%
|
-62.66
|
| Net Income Common Stockholders |
|
-30.07
+25.11%
|
-40.16
+36.24%
|
-62.98
-60.24%
|
-39.31
|
| Diluted EPS |
|
-15.85
+57.98%
|
-37.72
+39.36%
|
-62.20
-35.81%
|
-45.80
|
| Basic EPS |
|
-15.85
+57.98%
|
-37.72
+39.36%
|
-62.20
-35.81%
|
-45.80
|
| Basic Average Shares |
|
1.90
+78.22%
|
1.06
+1.29%
|
1.05
+22.43%
|
0.86
|
| Diluted Average Shares |
|
1.90
+78.22%
|
1.06
+1.29%
|
1.05
+22.43%
|
0.86
|
| Diluted NI Availto Com Stockholders |
|
-30.07
+25.11%
|
-40.16
+36.24%
|
-62.98
-60.24%
|
-39.31
|
| Line Item | Trend | 2023-12-31 |
|---|---|---|
| Total Assets |
|
18.22
|
| Current Assets |
|
14.73
|
| Cash Cash Equivalents And Short Term Investments |
|
12.78
|
| Cash And Cash Equivalents |
|
12.78
|
| Cash Financial |
|
—
|
| Other Short Term Investments |
|
0.00
|
| Receivables |
|
1.04
|
| Other Receivables |
|
1.04
|
| Taxes Receivable |
|
0.25
|
| Prepaid Assets |
|
0.46
|
| Restricted Cash |
|
0.07
|
| Other Current Assets |
|
0.38
|
| Total Non Current Assets |
|
3.48
|
| Net PPE |
|
2.33
|
| Gross PPE |
|
2.46
|
| Accumulated Depreciation |
|
-0.13
|
| Machinery Furniture Equipment |
|
0.26
|
| Other Properties |
|
2.20
|
| Other Non Current Assets |
|
1.16
|
| Total Liabilities Net Minority Interest |
|
7.00
|
| Current Liabilities |
|
5.61
|
| Payables And Accrued Expenses |
|
4.25
|
| Payables |
|
2.50
|
| Accounts Payable |
|
2.50
|
| Current Accrued Expenses |
|
1.75
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
0.00
|
| Current Debt And Capital Lease Obligation |
|
1.16
|
| Current Capital Lease Obligation |
|
1.16
|
| Other Current Liabilities |
|
0.19
|
| Total Non Current Liabilities Net Minority Interest |
|
1.39
|
| Long Term Debt And Capital Lease Obligation |
|
1.34
|
| Long Term Capital Lease Obligation |
|
1.34
|
| Other Non Current Liabilities |
|
0.05
|
| Stockholders Equity |
|
11.22
|
| Common Stock Equity |
|
11.22
|
| Capital Stock |
|
0.00
|
| Common Stock |
|
0.00
|
| Preferred Stock |
|
0.00
|
| Share Issued |
|
1.07
|
| Ordinary Shares Number |
|
1.07
|
| Treasury Shares Number |
|
0.00
|
| Additional Paid In Capital |
|
170.33
|
| Retained Earnings |
|
-159.11
|
| Gains Losses Not Affecting Retained Earnings |
|
0.01
|
| Other Equity Adjustments |
|
0.01
|
| Total Equity Gross Minority Interest |
|
11.22
|
| Total Capitalization |
|
11.22
|
| Working Capital |
|
9.13
|
| Invested Capital |
|
11.22
|
| Total Debt |
|
2.50
|
| Capital Lease Obligations |
|
2.50
|
| Net Tangible Assets |
|
11.22
|
| Tangible Book Value |
|
11.22
|
| Line Item | Trend | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-26.13
+35.41%
|
-40.45
+32.13%
|
-59.60
-78.44%
|
-33.40
|
| Cash Flow From Continuing Operating Activities |
|
-26.13
+35.41%
|
-40.45
+32.13%
|
-59.60
-78.44%
|
-33.40
|
| Net Income From Continuing Operations |
|
-30.07
+25.11%
|
-40.16
+36.24%
|
-62.98
-60.24%
|
-39.31
|
| Depreciation Amortization Depletion |
|
1.09
+19.13%
|
0.92
-2.56%
|
0.94
+176.18%
|
0.34
|
| Depreciation |
|
1.09
+19.13%
|
0.92
-2.56%
|
0.94
+176.18%
|
0.34
|
| Depreciation And Amortization |
|
1.09
+19.13%
|
0.92
-2.56%
|
0.94
+176.18%
|
0.34
|
| Other Non Cash Items |
|
-0.04
|
—
|
—
|
—
|
| Stock Based Compensation |
|
3.47
-2.53%
|
3.56
-64.57%
|
10.06
-56.87%
|
23.31
|
| Operating Gains Losses |
|
-0.18
-489.36%
|
0.05
+100.75%
|
-6.30
+73.02%
|
-23.36
|
| Gain Loss On Investment Securities |
|
-0.18
-489.36%
|
0.05
+100.75%
|
-6.30
+73.02%
|
-23.36
|
| Change In Working Capital |
|
-0.18
+95.75%
|
-4.19
-310.88%
|
-1.02
-118.19%
|
5.61
|
| Change In Receivables |
|
0.00
-100.00%
|
0.33
+64.00%
|
0.20
|
—
|
| Change In Prepaid Assets |
|
0.53
-56.68%
|
1.23
+138.89%
|
-3.16
-403.36%
|
1.04
|
| Change In Payables And Accrued Expense |
|
1.02
+127.33%
|
-3.74
-397.93%
|
1.25
-79.87%
|
6.23
|
| Change In Accrued Expense |
|
1.49
+168.68%
|
-2.17
-1142.31%
|
0.21
-95.59%
|
4.71
|
| Change In Payable |
|
-0.47
+70.15%
|
-1.57
-249.90%
|
1.05
-30.91%
|
1.51
|
| Change In Account Payable |
|
-0.47
+70.15%
|
-1.57
-249.90%
|
1.05
-31.54%
|
1.53
|
| Change In Other Working Capital |
|
-0.05
|
—
|
0.05
|
—
|
| Change In Other Current Assets |
|
-0.52
+51.81%
|
-1.08
-178.50%
|
1.37
+187.33%
|
-1.57
|
| Change In Other Current Liabilities |
|
-1.16
-24.41%
|
-0.93
-26.56%
|
-0.74
-720.00%
|
-0.09
|
| Investing Cash Flow |
|
0.21
-99.49%
|
41.50
+202.27%
|
-40.58
-671.74%
|
-5.26
|
| Cash Flow From Continuing Investing Activities |
|
0.21
-99.49%
|
41.50
+202.27%
|
-40.58
-671.74%
|
-5.26
|
| Capital Expenditure |
|
—
|
—
|
—
|
-5.26
|
| Capital Expenditure Reported |
|
—
|
—
|
0.00
+100.00%
|
-0.26
|
| Net Investment Purchase And Sale |
|
0.21
-99.49%
|
41.50
+202.27%
|
-40.58
|
0.00
|
| Purchase Of Investment |
|
-11.46
+3.03%
|
-11.82
+72.50%
|
-42.98
|
0.00
|
| Sale Of Investment |
|
11.68
-78.10%
|
53.32
+2121.71%
|
2.40
|
0.00
|
| Net Intangibles Purchase And Sale |
|
—
|
—
|
0.00
+100.00%
|
-5.00
|
| Purchase Of Intangibles |
|
—
|
—
|
0.00
+100.00%
|
-5.00
|
| Financing Cash Flow |
|
17.99
+15682.46%
|
0.11
-59.29%
|
0.28
-99.68%
|
88.45
|
| Cash Flow From Continuing Financing Activities |
|
17.99
+15682.46%
|
0.11
-59.29%
|
0.28
-99.68%
|
88.45
|
| Net Common Stock Issuance |
|
17.87
|
0.00
|
0.00
-100.00%
|
47.43
|
| Proceeds From Stock Option Exercised |
|
0.12
+3.51%
|
0.11
-59.29%
|
0.28
-99.32%
|
41.02
|
| Changes In Cash |
|
-7.92
-782.43%
|
1.16
+101.16%
|
-99.90
-300.63%
|
49.79
|
| Effect Of Exchange Rate Changes |
|
0.14
+437.50%
|
-0.04
-156.34%
|
0.07
+438.10%
|
-0.02
|
| Beginning Cash Position |
|
12.85
+9.55%
|
11.73
-89.48%
|
111.56
+80.55%
|
61.79
|
| End Cash Position |
|
5.07
-60.59%
|
12.85
+9.55%
|
11.73
-89.48%
|
111.56
|
| Free Cash Flow |
|
-26.13
+35.41%
|
-40.45
+32.13%
|
-59.60
-54.17%
|
-38.66
|
| Interest Paid Supplemental Data |
|
0.00
|
0.00
|
0.00
-100.00%
|
0.03
|
| Income Tax Paid Supplemental Data |
|
0.00
|
0.00
|
0.00
|
—
|
| Amortization Of Securities |
|
-0.21
+66.51%
|
-0.63
-115.75%
|
-0.29
|
0.00
|
| Common Stock Issuance |
|
17.87
|
0.00
|
0.00
-100.00%
|
47.43
|
| Issuance Of Capital Stock |
|
17.87
|
0.00
|
0.00
-100.00%
|
47.43
|
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|